Houston startup with unique vascular innovation enrolls subjects in new trial

medical device momentum

VenoStent's innovative medical device is officially enrolling subjects in a clinical trial. Image courtesy of VenoStent

A Houston-based company has enrolled the initial subjects in a first-of-its-kind trial.

VenoStent was created to improve vascular surgery outcomes for patients undergoing arteriovenous fistula (AVF) creation surgery.

“When a vein is connected to an artery, as in AVF creation, the vein experiences a 10x increase in pressure and flow that is traumatizing to veins. Many fail to become usable for dialysis,” Geoffrey Lucks, VenoStent COO and co-founder, says in a news release.

Enter VenoStent’s SelfWrap Bioabsorbable Perivascular Wrap, better known as simply SelfWrap. In May 2023, SelfWrap gained FDA approval to begin its US IDE Study, SAVE-FistulaS: The SelfWrap-Assisted ArterioVEnous Fistula Study.

Roughly half a million Americans need hemodialysis just to survive another day. Nearly all of those patients require a vascular access creation surgery, but the procedure has a 50-percent failure rate in its first year. VenoStent and SelfWrap are aimed at improving those odds. It works by using the body’s own healing mechanism.

SelfWrap is a flexible, bioabsorbable vascular wrap that helps to recreate the arterial environment in veins. Over time, the body replaces the SelfWrap with venous tissue.

The company has begun to enroll patients for what will eventually be a 200-subject study. Some of those people have radiocephalic fistulas, others have brachiocephalic ones. This is important, because it will likely prove that the technology works for most types of AVFs. The sites for this clinical trial are at the Surgical Specialists of Charlotte, P.A. in Charlotte, NC, and the Cardiothoracic and Vascular Surgeons in Austin.

“While it’s ambitious and sets a high bar for FDA Approval, we owe it to the chronic kidney disease (CKD) patient community to provide the highest level of clinical evidence,” Timothy Boire, CEO and cofounder, says in the release. “We’re confident based on years of preclinical and clinical data that we’ll demonstrate superiority to standard of care with this breakthrough technology.”

VenoStent recently completed a $16 million Series A, financed by Good Growth Capital and IAG Capital. This is the first-ever randomized controlled trial of a medical device designed to improve outcomes from arteriovenous fistula (AVF) creation surgery in the United States.

This week's roundup of Houston innovators includes Jeremy Pitts of Activate Houston, Tim Boire of VenoStent, and Kevin Knobloch of Greentown Labs. Photos courtesy

3 Houston innovators to know this week

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from medical device to climatetech — recently making headlines in Houston innovation.

Jeremy Pitts, managing director for Activate Houston

Jeremy Pitts has been named the inaugural Houston managing director for Activate. Photo via LinkedIn

Activate named Jeremy Pitts as the Houston managing director this month. The nonprofit, which announced its new Houston program earlier this year, was founded in Berkeley, California, in 2015 to bridge the gap between the federal and public sectors to deploy capital and resources into the innovators creating transformative products.

For Activate Houston, the challenge is to focus on finding and supporting innovators within the energy sector.

"There are so many reasons to be excited about the energy transition and overall innovation ecosystem in Houston — the region's leadership in energy and desire to maintain that leadership through the energy transition, the many corporations leading the charge to be part of that change who are speaking with their actions and not just their words, the incredible access to talent, the region's diversity, the list goes on and on," Pitts tells InnovationMap. Read more.

Tim Boire, CEO and co-founder of VenoStent

Tim Boire shares his company's roadmap on this week's episode of the Houston Innovators Podcast. Photo via LinkedIn

Commercializing a health tech innovation is a long game — fraught with regulatory obstacles, cyclical rounds of funding, and continuous improvement — all fueled by the desire to enhance treatment and save lives.

That's Tim Boire's plan. And it's a thorough one at that. On this week's episode of the Houston Innovators Podcast, Boire — president and CEO of VenoStent, a medical device startup that’s designing a unique material for hemodialysis patients — shares his roadmap for his company.

"We believe we can be pioneers of a paradigm shift in vascular surgery — to not just treat problems after they've already occurred, but actually prevent them from occurring in the first place," he says in the episode. Read more.

Kevin Knobloch , CEO of Greentown Labs

Kevin Knobloch will lead Greentown Labs as CEO. Photo via LinkedIn

While not based in Houston, Kevin Knobloch, who served as chief of staff of the United States Department of Energy in President Barack Obama’s second term, is definitely going to be someone to know in the innovation ecosystem. He will be CEO of Greentown Labs, effective September 5. In his role, Knobloch will oversee both Greentown locations in Houston and Somerville, Massachusetts, outside of Boston.

“I’m honored and thrilled to have the opportunity to once again pass the leadership baton,” Greentown Co-Founder Jason Hanna says, who has been serving as interim CEO. “Especially so given Kevin’s incredible record of climate leadership. I’m excited for the future of this organization and the impact he can make as Greentown enters the second decade of its climate mission.” Read more.

Tim Boire, CEO and co-founder of VenoStent, shares his company's roadmap on this week's episode of the Houston Innovators Podcast. Photo via LinkedIn

This Houston medical device innovator plans to lead a 'paradigm shift' in vascular surgery

HOUSTON INNOVATORS PODCAST EPISODE 199

Commercializing a health tech innovation is a long game — fraught with regulatory obstacles, cyclical rounds of funding, and continuous improvement — all fueled by the desire to enhance treatment and save lives.

That's Tim Boire's plan. And it's a thorough one at that. On this week's episode of the Houston Innovators Podcast, Boire — president and CEO of VenoStent, a medical device startup that’s designing a unique material for hemodialysis patients — shares his roadmap for his company.

"We believe we can be pioneers of a paradigm shift in vascular surgery — to not just treat problems after they've already occurred, but actually prevent them from occurring in the first place," he says in the episode.

VenoStent's most recent hurdle cleared is closing a $16 million series A round of venture funding. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round. The TMC Venture Fund also contributed.

Now, VenoStent is headed for a 200-patient trial in the United States, with an ultimate goal of product launch in 2026. The company's unique medical device is a bioabsorbable wrap that reduces vein collapse by providing mechanical support and promoting outward vein growth.

Boire had the idea for VenoStend when he was completing his PhD at Vanderbilt University. He completed the program, and then joined the HealthWildcatters accelerator in 2017 in Dallas. After that, Boire and his co-founder, Geoff Lucks, decided to take the leap and move to Houston to join JLABS at TMC. The rest, as they say, is history.

“Houston’s been a great place to hire,” Boire says. “We've been I think very fortunate to find our employees who are stellar, true believers in the technology — amazing engineers, and amazing people.”

And, of course, Boire has a plan to continue this hiring success. He says the goal is to grow to a team of 16 by the end of the year. Marketing and sales roles will likely be filled in 2025 ahead of product launch.

“When we think about what our mission is at VenoStent, it’s to ultimately improve patient care — and we are very passionate about this specific problem that patients experience and go through,” Boire says.

“That's what drives everything we're doing as a company to improve quality and length of life for patients who have chronic kidney disease that progresses to a point where they need dialysis to sustain life," he continues. "We believe that we can become the standard care for vascular surgery starting with hemodialysis access."

As VenoStent's trials and growth goes according to plan, Boire says this product can be used for other implications.

Boire shares more on his grand plan, plus how he weathered the storm that is fundraising at a time where so much venture capital activity has slowed. Listen to the interview here — or wherever you stream your podcasts — and subscribe for weekly episodes.

A Houston startup based out of the TMC Innovation Factory has announced funding and upcoming trials. Photo courtesy of TMC

Houston health tech startup secures $16M series A, prepares for first U.S. clinical trials

money moves

Fueled by fresh funding in the bank, a medical device startup has announced upcoming trials.

VenoStent, Inc., a company developing an innovative tool to improve outcomes for hemodialysis patients, has closed $16 million in a series A round of financing. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round.

The company also announced it received Investigational Device Exemption from the FDA for its United States clinical trial, SAVE-FistulaS.

“Our mission at VenoStent is to improve the quality and length of life of dialysis patients. On the heels of our very promising results in several preclinical studies and a 20-patient feasibility study that led to our Breakthrough Designation last year, this recent IDE approval is perhaps our biggest milestone to date," Tim Boire, CEO of VenoStent, says in a news release. "We now enter an exciting new epoch in our company’s development that we believe will ultimately result in FDA Approval and vastly improve the quality and length of life for patients."

VenoStent's novel therapeutic medical device is a bioabsorbable wrap. Image courtesy of VenoStent

VenoStent's series A will fund the trial, expand manufacturing capabilities, and more. The company is targeting the more than 800,000 people in the U.S. with end-stage renal disease. Currently, more than half of the surgeries performed to initiate hemodialysis fail within a year. VenoStent's novel therapeutic medical device is a bioabsorbable wrap that reduces vein collapse by providing mechanical support and promoting outward vein growth.

“This trial is designed to provide the highest level of clinical evidence. We’re excited to be in this position to treat the first patients in the United States with this technology, and demonstrate the safety and efficacy of our device,” continues Boire in the release.

Per the release, the company is aiming for FDA Approval and be the first-to-market device to improve hemodialysis access surgery.

“We’re extremely pleased to be partnering with VenoStent on this critical mission. This company and technology are poised for commercial success to address a critical, unmet need,” says Bob Crutchfield, operating partner at Good Growth Capital, in the release.

The TMC Venture Fund also contributed to the series A investment round, along with SNR, Baylor Angel Network / Affinity Fund, Creative Ventures, Cowtown Angels, Alumni Ventures, and other notable angel investors. Past investors in VenoStent include KidneyX, National Science Foundation, National Institute of Health, Y Combinator, Health Wildcatters, and the Texas Halo Fund.

“VenoStent’s data and traction to date is impressive and gives us a lot of confidence in their continued success. We look forward to helping them get this Breakthrough product to market and help patients that are in dire need of this innovative technology,” says Joel Whitley, partner at IAG Capital Partners, in the release.

Tim Boire is the CEO of VenoStent. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

10+ can't miss Houston business and innovation events for May

WHERE TO BE

From pitching competitions to expert speaker summits, May is chock-full of opportunities for Houston innovators.

Here's a roundup of events you won't want to miss out on so mark your calendars and register accordingly.

Note: This post may be updated to add more events.


May 2 — State of Houston's Global Economy

Explore the complexities of Houston's global economy, dissect the challenges and opportunities that lie ahead and chart a course for sustainable growth in the years to come at this business conference sponsored by the Greater Houston Partnership. Highlighting the day will be a presentation by the Partnership’s Chief Economist, Patrick Jankowski who will share his insights into the role global trade plays in the region’s growth.

Panel conversation speakers include:
  • Kurt Heim, Vice President of Environmental Advancement, Daikin Comfort
  • Moderator: George Y. Gonzalez, Partner, Haynes Boone, LLP
This event is Thursday, May 2, from 8:15 to 10 am at Partnership Tower. Click here to register.

May 3 — Transformative Healthcare Innovations Across the TMC

This symposium is filled with discussions, presentations, and networking opportunities. Discover the latest advancements in healthcare technology and how they are shaping the future of medicine. The event will be held in person at the TMC3 Collaborative Building, so come ready to engage with industry experts and fellow healthcare enthusiasts.

This event is Friday, May 3, from 9 am to 3:30 pm at TMC3 Collaborative Building. Click here to register.

May 6 to 9 — Offshore Technology Conference.

Since 1969, the Offshore Technology Conference (OTC) has served as a central hub convening energy professionals from around the world to share ideas and innovations, discuss, debate, and build consensus around the most pressing topics facing the offshore energy sector.

This conference is Monday, May 7, to Thursday, May 9, at NRG Park. Click here to register.

May 7 — Small Business Awards Houston 

This year's awards luncheon event theme will be "The SBA Awards presented by SCORE are going to Space" celebrating Houston's advances into space with two fantastic guest speakers and the optional “How to do business with NASA” workshop. The keynote speakers will be Stephanie Murphy, Aegis Aerospace and Arturo Machuca, Director of the Houston Spaceport.

This event is Tuesday, May 7, from 11 am to 1:30 pm at Royal Sonesta Galleria Houston. Click here to register.

May 7 — Tech + Tequila Talk: Goal Park Innovation

At the upcoming edition of Tech+Tequila talk, hear the process behind activating public spaces like Goal Park. Specifically, explore how innovation plays a key role in creating a safer and more dynamic environment for the community. Join in discussions on the intersection of art, philanthropy, and urban development, and learn how projects like Goal Park are shaping the future of our cities.

This event is Tuesday, May 7, from 6 to 8 pm at Niels Esperson Building. Click here to register.

May 13 — TECHSPO Houston 2024 Technology Expo

TECHSPO Houston brings together developers, brands, marketers, technology providers, designers, innovators and evangelists looking to set the pace in advancing technology. Watch exhibitors showcase the next generation of advances in technology & innovation, including; Internet, Mobile, AdTech, MarTech and SaaS technologies.

This event is Monday, May 13, from 9 am to 7 pm at Marriott Marquis. Click here to register.

May 14 — An Evening with Johnson & Johnson's Immunology Team

Johnson & Johnson Innovative Medicine Immunology Team will present our strategic priorities in the space as part of our search for promising scientific innovations.

The focus areas of the program include bispecifics for auto-immune and inflammatory diseases, multispecific T-cell engagers for deep cell depletion, and tissue T-Reg / stromal immune modulators. After the programming concludes, there will be an opportunity to network at the reception with industry leaders and like-minded innovators. This networking session will provide attendees with a chance to discuss ideas, and further explore collaboration opportunities

This event is Tuesday, May 14, from 4 to 7 pm at Texas Medical Center. Click here to register.

May 16 — Energy Underground

The Energy Underground is a group of professionals in the Greater Houston area that are accelerating the Energy Transition. Make industry contacts, secure financing, share deals, recommend talent looking to enter the energy workforce at this meeting of like-minded innovators.

This event is Thursday, May 16, from 12 to 1 pm at the Cannon West Houston. Click here to register.

May 16 — UH Tech Bridge: Innov8Hub Pitch Day

This event is your chance to immerse yourself in the vibrant startup ecosystem, network with industry experts, and discover the next big thing. Get ready to witness groundbreaking ideas and cutting-edge pitches from talented individuals.

This event is Thursday, May 16, from 5 to 7:30 pm at UH Tech Bridge. Click here to register.

May 18 — Create by Getty Images Houston 2024

Head to this event to shoot a variety of ready-to-upload content for your portfolio and enjoy priceless creative development opportunities. Connect with fellow creators, collaborators, and peers to expand your network and build meaningful relationships. Participate in interactive workshops to enhance your skills and knowledge and gain actionable takeaways for creative endeavors.

This event starts Saturday, May 18, at 8:30 am at The Cannon West Houston. Click here to register.

May 22 — Pearland Innovation Hub Anniversary

Come for an evening filled with innovation, creativity, and fun. Attendees will have an opportunity to meet some members, partners, and sponsors of Pearland Innovation Hub.

This event is Wednesday, May 22, from 6 to 8 pm at Spacio.us. Click here to register.

May 28 — Texas Small Business Expo

Texas Small Business Expo is a trade show, educational business to business conference, exhibition & networking event for entrepreneurs, start-ups and anyone that owns a business or looking to start their own business. Learn how to solve challenging business issues by discussing strategies, acquire valuable knowledge from those in your business and connect with top vendors in various industries.

This event is Tuesday, May 28, from 4 to 9 pm at Wakefield Crowbar. Click here to register.

May 29 — Bayou City Bio Pulse at Gensler

Join the GHP for its next Bayou City Bio Pulse, hosted by global architecture, design and planning firm, Gensler. This event will feature panel discussions, tours of Gensler’s space, VR walkthroughs and more.

This event is Wednesday, May 29, from 4 to 6 pm at Gensler's office (2 Houston Center). Click here to register.

Texas lands in top 10 states expected to be most financially affected by weather events

report

Texas — home to everything from tornadoes to hurricanes — cracks the top 10 of a new report ranking states based on impact from weather-related events.

SmartAsset's new report factored in a myriad of data from the Federal Emergency Management Agency to identify which states face the most financial risk due to various weather events. In the report, the states were ranked by the total expected annual financial losses per person. Texas ranked at No. 10.

"With a variety of environmental events affecting the wide stretch of the United States, each state is subject to its own risks," reads the report. "Particularly, tornadoes, wildfires, hurricanes, flooding, landslides, lightning and drought, among other events, can cause damage to buildings, agriculture and individuals alike. When considering insurance, residents and business owners in each state should account for historic and projected losses due to environmental events in their financial plans."

In Texas, the total expected annual loss per person is estimated as $283.15. The report broke down each weather event as follows:

  • Coastal flooding: $1.49
  • Drought: $3.48
  • Earthquake: $1.71
  • Heat wave: $8.16
  • Hurricane: $89.22
  • Riverine flooding: $66.05
  • Strong wind: $5.37
  • Tornado: $71.04
  • Wildfire: $8.26
  • Winter weather: $1.96
Louisiana ranked as No. 1 on the list with $555.55 per person. The state with the lowest expected loss per person from weather events was Ohio with only $63.89 estimated per person.


------

This article originally ran on EnergyCapital.

Exclusive: Houston hydrogen spinout names energy industry veteran as CEO

good as gold

Cleantech startup Gold H2, a spinout of Houston-based energy biotech company Cemvita, has named oil and gas industry veteran Prabhdeep Singh Sekhon as its CEO.

Sekhon previously held roles at companies such as NextEra Energy Resources and Hess. Most recently, he was a leader on NextEra’s strategy and business development team.

Gold H2 uses microbes to convert oil and gas in old, uneconomical wells into clean hydrogen. The approach to generating clean hydrogen is part of a multibillion-dollar market.

Gold H2 spun out of Cemvita last year with Moji Karimi, co-founder of Cemvita, leading the transition. Gold H2 spun out after successfully piloting its microbial hydrogen technology, producing hydrogen below 80 cents per kilogram.

The Gold H2 venture had been a business unit within Cemvita.

“I was drawn to Gold H2 because of its innovative mission to support the U.S. economy in this historical energy transition,” Sekhon says in a news release. “Over the last few years, my team [at NextEra] was heavily focused on the commercialization of clean hydrogen. When I came across Gold H2, it was clear that it was superior to each of its counterparts in both cost and [carbon intensity].”

Gold H2 explains that oil and gas companies have wrestled for decades with what to do with exhausted oil fields. With Gold H2’s first-of-its-kind biotechnology, these companies can find productive uses for oil wells by producing clean hydrogen at a low cost, the startup says.

“There is so much opportunity ahead of Gold H2 as the first company to use microbes in the subsurface to create a clean energy source,” Sekhon says. “Driving this dynamic industry change to empower clean hydrogen fuel production will be extremely rewarding.”

In 2022, Gold H2 celebrated its successful Permian Basin pilot and raised early-stage funding. In addition to Gold H2, Cemvita also spun out a resource mining operation called Endolith. In a podcast episode, Karimi discussed Cemvita's growth and spinout opportunities.

View All Listings